奥希替尼联合贝伐珠单抗对比奥希替尼单药作为EGFR突变伴获得性T790M突变晚期NSCLC二线靶向治疗的随机II期研究:欧洲胸部肿瘤平台(ETOP 10-16)BOOSTER试验
BOOSTER是一项开放标签随机II期试验,纳入155例EGFR突变伴获得性T790M突变且既往EGFR TKI治疗失败的晚期NSCLC患者,随机接受奥希替尼联合贝伐珠单抗或奥希替尼单药治疗。主要终点无进展生存期在两组间无差异(联合组15.4个月 vs 奥希替尼组12.3个月,HR=0.96,P=0.83)。联合组≥3级治疗相关不良事件更常见(47% vs 18%)。
要点
- 联合组与奥希替尼单药组中位PFS无差异:15.4个月 vs 12.3个月,HR=0.96,P=0.83
- 两组客观缓解率均为55%,联合组至治疗失败时间显著更短(8.2个月 vs 10.8个月,P=0.0074)
- 联合组≥3级治疗相关不良事件发生率为47%,奥希替尼单药组为18%
核心结论
- 奥希替尼联合贝伐珠单抗与奥希替尼单药相比,未观察到无进展生存期差异。
- 联合组≥3级治疗相关不良事件更常见。
研究设计与样本
- BOOSTER为开放标签随机II期试验,研究奥希替尼80 mg每日联合贝伐珠单抗15 mg/kg每3周对比奥希替尼单药的疗效与安全性。
- 纳入既往EGFR TKI治疗失败后EGFR突变伴获得性T790M突变的晚期NSCLC患者。
- 2017年5月至2019年2月共随机155例患者(联合组78例,奥希替尼组77例)。
- 主要终点为研究者评估的无进展生存期,次要终点包括总生存期、客观缓解率和不良事件。
主要发现
- 数据截止2021年2月22日,中位随访33.8个月(四分位距26.5-37.6个月),意向治疗人群中报告129例(83.2%)PFS事件。
- 联合组中位PFS为15.4个月(95%CI 9.2-18.0个月),奥希替尼组为12.3个月(95%CI 6.2-17.2个月),分层log-rank P=0.83,HR=0.96(95%CI 0.68-1.37)。
- 联合组中位OS为24.0个月(95%CI 17.8-32.1个月),奥希替尼组为24.3个月(95%CI 16.9-37.0个月),分层log-rank P=0.91,HR=1.03(95%CI 0.67-1.56)。
- 探索性分析显示吸烟史与治疗对PFS存在显著交互作用(校正P=0.0052),吸烟者HR=0.52(95%CI 0.30-0.90),从不吸烟者HR=1.47(95%CI 0.92-2.33)。
- 两组客观缓解率均为55%;联合组中位至治疗失败时间显著短于奥希替尼组,分别为8.2个月 vs 10.8个月(P=0.0074)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M mutations, progression inevitably occurs. The angiogenic pathway is implicated in EGFR TKI resistance. PATIENTS AND METHODS: BOOSTER is an open-label randomised phase II trial investigating the efficacy and safety of combined osimertinib 80 mg daily and bevacizumab 15 mg/kg every 3 weeks, versus osimertinib alone, in patients with EGFR-mutant advanced NSCLC and acquired T790M mutations after failure on previous EGFR TKI therapy. Primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR) and adverse events (AEs). RESULTS: Between May 2017 and February 2019, 155 patients were randomised (combination: 78; osimertinib: 77). At data cut-off of 22 February 2021, median follow-up was 33.8 months [interquartile range (IQR): 26.5-37.6 months] and 129 (83.2%) PFS events were reported in the intention-to-treat population. There was no difference in median PFS between the combination [15.4 months; 95% confidence interval (CI) 9.2-18.0 months] and osimertinib arm (12.3 months; 95% CI 6.2-17.2 months; stratified log-rank P = 0.83), [hazard ratio (HR) = 0.96; 95% CI 0.68-1.37]. Median OS was 24.0 months (95% CI 17.8-32.1 months) in the combination arm and 24.3 months (95% CI 16.9-37.0 months) in the osimertinib arm (stratified log-rank P = 0.91), (HR = 1.03; 95% CI 0.67-1.56). Exploratory analysis revealed a significant interaction of smoking history with treatment for PFS (adjusted P = 0.0052) with a HR of 0.52 (95% CI 0.30-0.90) for smokers, and 1.47 (95% CI 0.92-2.33) for never smokers. ORR was 55% in both arms and the median time to treatment failure was significantly shorter in the combination than in the osimertinib arm, 8.2 months versus 10.8 months, respectively (P = 0.0074). Safety of osimertinib and bevacizumab was consistent with previous reports with grade ≥3 treatment-related AEs (TRAEs) reported in 47% and 18% of patients on combination and osimertinib alone, respectively. CONCLUSIONS: No difference in PFS was observed between osimertinib plus bevacizumab and osimertinib alone. Grade ≥3 TRAEs were more common in patients on combination.
引用
- Soo RA, Han JY, Dafni U, et al. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol. 2021. PMID: 34839016. doi:10.1016/j.annonc.2021.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。